Improving Human Papillomavirus-Related Cervical Cancer Screening in Patients With Systemic Lupus Erythematosus

REFERENCES

1. 1.↵
   1. Andreoli L,
   2. Bertsias GK,
   3. Agmon-Levin N, et al.

   EULAR recommendations for women’s health and the management of family planning, assisted reproduction, pregnancy and menopause in patients with systemic lupus erythematosus and/or antiphospholipid syndrome. Ann Rheum Dis 2017;76:476-85.

   OpenUrlAbstract/FREE Full Text
2. 2.↵
   1. Chung SH,
   2. Oshima K,
   3. Singleton M, et al.

   Determinants of cervical cancer screening patterns among women with systemic lupus erythematosus. J Rheumatol 2022;49:1236-41.

   OpenUrlAbstract/FREE Full Text
3. 3.↵
   1. Haute Autorité de Santé

   . Evaluation of human papillomavirus (HPV) tests for primary screening of precancerous and cancerous lesions of the cervix and the role of p16/Ki67 dual immunostaining. Public health guidelines summary; 2019. [Internet. Accessed May 15, 2023.] Available from: https://www.has-sante.fr/upload/docs/application/pdf/2019-09/synthese_anglais_hpv.pdf
4. 4.↵
   1. Moscicki AB,
   2. Flowers L,
   3. Huchko MJ, et al.

   Guidelines for cervical cancer screening in immunosuppressed women without HIV infection. J Low Genit Tract Dis 2019;23:87-101.

   OpenUrlCrossRef
5. 5.↵
   1. Zard E,
   2. Arnaud L,
   3. Mathian A, et al.

   Increased risk of high grade cervical squamous intraepithelial lesions in systemic lupus erythematosus: A meta-analysis of the literature. Autoimmun Rev 2014;13:730-5.

   OpenUrlCrossRefPubMed
6. 6.↵
   1. Bass AR,
   2. Chakravarty E,
   3. Akl EA, et al.

   2022 American College of Rheumatology guideline for vaccinations in patients with rheumatic and musculoskeletal diseases. Arthritis Rheumatol 2023;75:333-48.

   OpenUrl